Background Introduction

Ferritin (FER) is an iron containing protein, which widely exists in various mammalian organs such as liver, spleen, kidney and bone marrow, especially spleen and liver. The detection of serum ferritin can not only judge the iron storage in the body, diagnose iron deficiency anemia and iron overload, and investigate the nutritional status, but also can be used as a tumor marker to serve as reference for the diagnosis of some clinical malignant tumors, especially liver cancer.

When liver cancer occurs, the ferritin synthesized by cancer cells increases. Meanwhile, the liver function deteriorates since the liver cells are damaged, and the ferritin stored in the cytoplasm of liver cells overflows into the blood, increasing the serum ferritin concentration. Therefore, it can be used for early detection of liver cancer. In addition, during the treatment of liver cancer, the decrease of serum ferritin indicates that the treatment is effective, while its increase marks the deterioration and reoccurrence of liver cancer and its constant increase marks a poor prognosis. Therefore, the determination of serum ferritin can be used as one of the monitoring methods for the therapeutic effect of liver cancer treatment, especially for patients with negative AFP. 

Recommended Diagnostic Raw Materials

[Product Information]  

[Product Advantages]  

✦High Sensitivity

✦High Clinical Agreement Rate

✦High Specificity

[Product Performance]  

Colloidal Gold Platform

(1) On the colloidal gold platform, the FER paired monoclonal antibody was used to detect control samples of different concentrations, and it is obviously detected at 4.9ng/mL and concluded that the minimum detection limit of FER antibody pairing is 5ng/mL.

(2)On the colloidal gold platform, the FER paired monoclonal antibody test showed no cross reaction with 100ng/ml AFP, 35mg/ml HAS, 3.5mg/ml HSA.

Fluorescence Tomography Platform

(1)On the fluorescence tomography platform, the FER paired monoclonal antibody was used to detect the serum assigned by R company renowned internationally with a sample agreement rate of R2>99%.

(2)On the fluorescence tomography platform, the FER paired monoclonal antibody test showed no cross reaction with 100ng/ml AFP, 50ng/ml AFP, 35mg/ml HAS, 17.5mg/ml HSA.

[Company Background]

Qingdao Henderson Biotechnology Co., Ltd, established in 2016, serves as a professional supplier of core raw materials for in vitro diagnostic reagents and is committed to providing high-quality raw materials for global in vitro diagnostic reagent production enterprises, scientific research institutions and other fields.

The company provides the following staple products: antigens, antibodies, enzymes, etc., widely used in the detection of drug, respiratory infectious diseases (A, B, COVID-19 antigen, COVID-19 antibody, COVID-19 neutralizing antibody, syncytial virus, etc.), other infectious diseases (hepatitis, AIDS, tuberculosis, etc.), markers for tumor, inflammation, myocardial markers, animal diseases detection (dog, cat diseases) and other fields. 

The company, after years of development, has established several specialized laboratories and SPF experimental animal bases, a comprehensive and systematic R&D verification platform and formed a professional technical service team to provide personalized customized services and one-stop solutions.

Qingdao Henderson Biotechnology Co., Ltd is willing to build a renowned product brand for all customers with high-quality products and professional services to keep a foothold in the market with its sound competitiveness.

Limited space only allows the introduction of major products. You are welcomed to contact Qingdao Henderson Biotechnology Co., Ltd and acquire trial samples if you need more information.

Qingdao Henderson Biotechnology Co., Ltd.

Official Website: http://www.qdhenderson.com/

Tel: 0532-84670782
E-mail: info@qdhenderson.com